Villumsen et al. [13] organised a large-scale epidemiological survey, which suggested that the administration of GLP-1 receptor agonists and/or DPP-4 inhibitors can improve the process of IBD to a great extent. Here, GLP1R is linked to inflammatory bowel disease.